The Phase Ia trial is designed to assess the safety and efficacy of the company’s drug designed to target chemicals thought to be a cause of Alzheimer’s disease.

Topline results from a phase 2b/3 clinical trial of blarcamesine for individuals with early-stage Alzheimer’s disease showed ...

Gryphon Bio, Inc. has announced its pursuit of observational clinical studies with partners at multiple U.S. and ...

Delray Medical Center cut the ribbon on its newest high-tech machine that targets brain areas to treat movement disorders ...

Sleep disturbances encompass a broad range of disorders, such as insomnia, restless legs syndrome, parasomnias, sleep-disordered breathing, daytime ...

A new study from Karolinska Institutet and Mayo Clinic has revealed important insights into brain degeneration in dementia ...

Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company's commitment to developing genetically-validated th ...

By 2060, new dementia cases per year could double to one million because of the growing population of older Americans, a ...

A new study finds that dementia cases will increase at a much higher rate than expected, with lifetime risk rising to 42 ...

ProMIS Neurosciences Inc. (Nasdaq: PMN) (ProMIS), a clinical-stage biotechnology company focused on the generation and ...

Groundbreaking research reveals potential link between cytomegalovirus (CMV) and Alzheimer's disease, offering new insights ...

A predictive tool for determining the age at which individuals may develop mild cognitive impairment (MCI) or Alzheimer's ...